US and UK fast track designations for Parkinson’s gene therapy
Drug Discovery World
JULY 12, 2024
AB-1005 is an investigational adeno-associated virus 2 glial cell line-derived neurotrophic factor (AAV2-GDNF) neurorestorative gene therapy. The company’s Phase II REGENERATE-PD clinical trial is currently enrolling patients in the US with sites in the European Union and the UK planned to open later this year.”
Let's personalize your content